Leaderboard
Anzeige
Fr
|
De
Feedback
|
Impressum
|
Sitemap
Aucun choix d'articles!
Panier
Vous êtes ici:
Recherche de documentation spécialisée
»
Pancréas
»
Néoplasie
15. Avril 2026
Recherche
Gastroplattform
Néoplasie
Recherche avancée
Dépistage / diagnostic
Traitements
Directives
Perfectionnement
Nouvelles
Recherche de documentation spécialisée
Voies biliaires
Foie
Estomac / intestins
Œsophage
Pancréas
Néoplasie
Pancréatite
Autres
Congrès et sessions
Services et outils
Liens
Rect Top
Anzeige
Écriture:
Page 1 de 2986
Articles 1 - 20 / 59714
Extracellular Vesicles in Pancreatic Cancer Function and Potential Clinical Applications.
Onco Targets Ther
Li D, Fang JJ, Jiang ZL.
PMID: 41982335 [PubMed]
Myeloproliferative neoplasm as a cause of splanchnic vein thrombosis.
BMJ Case Rep
Abboud B, Taha I, Shah Z, Shildt A, Rischall A, Wheeler J.
PMID: 41980793 [PubMed - indexed for MEDLINE]
Laparoscopic versus open partial hepatectomy for hepatocellular carcinoma in F4 cirrhosis: A propensity score-matched study of perioperative safety.
Ann Hepatobiliary Pancreat Surg
Sugita H, Nakanuma S, Tokoro T, Takei R, Okazaki M, Kato K, Takada S, Makino I, Yagi S.
PMID: 41978319 [PubMed - as supplied by publisher]
The effect of LysaKare infusion on serum potassium levels in patients with gastroenteropancreatic neuroendocrine tumours eligible for treatment with [(177)Lu]Lu-DOTA-TATE: A post-authorisation safety study.
J Neuroendocrinol
Hofland J, Grana CM, Weickert MO, Moore AR, Shah T, Prakash V, Kolasi, de Herder WW, Spada F, Xu L, Fite R, Wu Y, .
PMID: 41978231 [PubMed - indexed for MEDLINE]
High Intratumoral PROS1 Expression Correlates with Improved Survival and Is Associated with Suppressed Oncogenic Signaling in Pancreatic Ductal Adenocarcinoma.
Int J Mol Sci
Prouse T, Majumder R, Majumder S.
PMID: 41977152 [PubMed - indexed for MEDLINE]
Comparison of Comprehensive Serum miRNA Sequencing and Apolipoprotein A2 Isoforms for Early Detection of Pancreatic Cancer.
Cancers (Basel)
Kashima H, Kawai M, Iimori K, Nagao M, Morikawa TJ, Otomo R, Hirai M, Minaga K, Asada M, Umemura A, Uenoyama Y, Morita T, Yazumi S, Minami R, Marui S, Yamauchi Y, Nakai Y, Takada Y, Shio S, Yoshioka T, Kanda N, Masuda T, Nagai K, Hatano E, Fukuda A, Seno H.
PMID: 41976399 [PubMed]
Systematic Review and Meta-Analysis of Current and Novel Approaches in the Management of Borderline Resectable and Locally Advanced Pancreatic Cancer.
Cancers (Basel)
Le K, Le KDR, Hong W, Gibbs P, Yoshino O, Lee B.
PMID: 41976359 [PubMed]
Surgical Perspectives on Neoadjuvant Therapy in Borderline Resectable and Locally Advanced Pancreatic Cancer.
Cancers (Basel)
Zhang J, Geng M, Friess H, Demir IE, Scheufele F.
PMID: 41976353 [PubMed]
Cardiovascular Risk in Pancreatic Cancer: A Meta-Analysis of 197 Studies.
Cancers (Basel)
Németh J, Lee J, Eperjesi O, Gagyi EB, Bánfalvi Z, Lillik V, Creanga-Murariu I, Tóth R, Szalai EÁ, Obeidat M, Váncsa S, Bunduc S, Hegyi P.
PMID: 41976330 [PubMed]
Therapeutic Potential of miR-4711-5p in Pancreatic Cancer: Antitumor Activity and Mechanistic Insights.
Cancers (Basel)
Yokoyama Y, Morimoto Y, Yamamoto H, Kouda S, Kawanami S, Yang R, Zhang Y, Tsujimoto M, Nagata N, Shimomura Y, Nishida K, Hata T, Inoue A, Shibata S, Yamamoto H, Mori M.
PMID: 41976327 [PubMed]
Pathogenesis, Diagnostic Pathways, and New Therapeutic and Nutritional Strategies for Pancreatic Cancer-Associated Cachexia.
Cancers (Basel)
Klus W, Ossowska J, Kowalcze K, Kiliszczyk A, Paziewska A.
PMID: 41976282 [PubMed]
EGFR ligand Angiogenin predicts response to ALK5 inhibition in pancreatic cancer via a TNF-α paracrine axis in tumor-associated macrophages.
Oncogene
Pietrobono S, De Vita V, Mangiameli D, Aparo A, Lorenzo ES, Bonato A, Bertolini M, Scarlato E, Casalino S, Quinzii A, Zecchetto C, Melisi D.
PMID: 41975075 [PubMed - as supplied by publisher]
Human endogenous retroviruses in liver cancer: a double-edged sword in tumor progression and anti-tumor immunity.
Crit Rev Oncol Hematol
Jiang X, Huang Z, Zhong Y, Lv W, Zhou R, Wang J, Liu J.
PMID: 41974391 [PubMed - as supplied by publisher]
Towards transparent and interpretable screening: multi-biofluid FTIR spectroscopy with LLM-Augmented explainability for pancreatic cancer detection.
Methods
Tang Z, Irvine O, Duckworth E, Costanzo C, Lillis K, Ren J, Anupama Bandaranayake PM, Sarireh BA, Mortimer M, Kanamarlapudi V, Higginbotham V, Chandrashekhara SH, Mora B, Roy D.
PMID: 41974239 [PubMed - as supplied by publisher]
Malpractice claims for pancreatic cancer in Norway: claim-rates, injury domains, claim outcomes and indemnity compensation.
Acta Oncol
Søreide AH, Edland KH, Alvestad AB, Hodne S, Søreide K.
PMID: 41972913 [PubMed - indexed for MEDLINE]
Decoding Drug Resistance in Pancreatic Cancer: A Subcellular Structure Perspective.
Biology (Basel)
Li X, Lyu H, Wu Y, Chen A, Wu G, Zhang R, Xiao S, Guo D, Zhang Q, Yan C, Tang J, Zhou C.
PMID: 41972577 [PubMed]
Immune Evasion of Helicobacter pylori and Extra-Gastric Cancer Risk.
J Gastroenterol Hepatol
Engin ED, Engin AB, Engin A.
PMID: 41972361 [PubMed - as supplied by publisher]
Targeted drug delivery systems for pancreatic cancer therapy: advances, challenges, and future perspectives.
Front Immunol
Zhang X, Tao X, Zhang Y, Gan G, Lv J, Zhang L, Dong D.
PMID: 41972173 [PubMed - indexed for MEDLINE]
mRNA vaccines in oncology: personalized cancer immunization and neoantigen targeting.
Mol Cell Oncol
Parganiha M, Rathored J, Sai Painkra D.
PMID: 41971684 [PubMed]
The development and validation of a machine learning algorithm for identifying lateral lymph nodes skip metastasis in papillary thyroid cancer.
Front Oncol
Cheng G, Zhang X, Cheng L, Ruan Y, Qiu Y.
PMID: 41971436 [PubMed]
Articles 1 - 20 / 59714
Page 1 de 2986
Rect Bottom
Anzeige
Adserver Footer
Intervalle de temps demandé
--sans limitation--
1 Week
1 Month
3 Months
6 Months
1 Year
2 Years
3 Years
5 Years
10 Years
Sky right 1
Anzeige
Mediscope AG E-mail:
info@mediscope.ch
Disclaimer
|
Privacy Policy
|
Publicité